Home > Insider Trading > Filing (0001144204-15-041465)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1270073	Intercept Pharmaceuticals Inc	ICPT	Pharmaceutical Preparations (2834)	223868459

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1559569	Mark Pruzanski	C/O Intercept Pharmaceuticals, Inc. 450 W. 15Th Street, Suite 505 New York NY 10011	Ceo & President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-07-01	4,868	$0.00	507,172	No	4	M	Direct
Common Stock	Disposition	2015-07-02	149	$236.13	507,023	No	4	S	Direct
Common Stock	Disposition	2015-07-02	7	$238.16	507,016	No	4	S	Direct
Common Stock	Disposition	2015-07-02	2	$239.00	507,014	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2015-07-01	4,868	$0.00	4,868	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,735			No	4	M	Direct

Footnotes

Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee.
Conversion of restricted stock units ("RSUs") to shares of common stock on a one-to-one basis.
On November 16, 2012, the reporting person was granted 77,884 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 6.25% of the shares underlying the RSUs, became vested on July 1, 2015, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares underlying the RSUs will vest pro rata on a quarterly basis from October 1, 2015 through January 1, 2016, subject to the terms and conditions of the award and the 2012 Plan.